A study comparing predictive factors of 1 year visual outcome in ranibizumab monotherapy group with combination group treated with ranibizumab and photodynamic therapy.
Phase of Trial: Phase IV
Latest Information Update: 15 May 2017
At a glance
- Drugs Ranibizumab (Primary) ; Verteporfin
- Indications Age-related macular degeneration; Choroidal neovascularisation
- Focus Therapeutic Use
- 15 May 2017 New trial record